Table 4.

Univariate and multivariate analyses for overall survival

Variables	Univariate analysis			Multivariate analysis
	HR	95% CI	P-value	HR	95% CI	P-value
Fatigue/asthenia/malaise	0.9	0.53–1.51	0.687
Diarrheaa	0.5	0.29–0.86	0.012	0.55	0.33–0.92	0.023
PPES	0.72	0.40–1.30	0.276
Rashb	0.77	0.39–1.52	0.449
Proteinuria	1.22	0.71–2.10	0.477
Baseline ECOG PS (0 vs. ≥ 1)				0.44	0.27–0.73	0.001
Prior VEGF therapy (0 vs. 1)				0.68	0.4–1.15	0.151
Baseline weight (kg)				0.99	0.98–1.00	0.174
Age (years)				1.01	0.98–1.03	0.64
Region (Europe vs. Other)				0.92	0.49–1.74	0.806
Region (North America vs. Other)				0.75	0.34–1.63	0.462
Histology (Follicular vs. papillary)				0.36	0.19–0.68	0.002

CI, confidence interval, ECOG PS, Eastern Cooperative Oncology Group performance status, HR, hazard ratio, PPES, palmar-plantar erythrodysesthesia syndrome, VEGF, vascular endothelial growth factor

^a Includes diarrhea, colitis, bowel movement irregularity, frequent bowel movements, functional gastrointestinal disorder, gastrointestinal disorder, and change in bowel habit

^b Includes macule, papule, rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic